Pharmaceutical Rasagiline Obesity Killer Raw Material CAS 136236-51-6 White Powder
 
Quick detail

 
Rasagiline Description

Rasagiline (Azilect, TVP-1012, N-propargyl-1(R)-aminoindan) is an irreversible inhibitor of monoamine oxidase-B used as a monotherapy to treat symptoms in early Parkinson's disease or as an adjunct therapy in more advanced cases.
The racemic form of the drug was invented by Aspro Nicholas in the early 1979s. Moussa B.H. Youdim identified it as a potential drug for Parkinson's disease, and working with collaborators at Technion– Israel Institute of Technology in Israel and the drug company, Teva Pharmaceutical, identified the R-isomer as the active form of the drug.
 
Rasagiline Usage 

 
Do NOT use rasagiline if:

• you are allergic to any ingredient in rasagiline

• you have moderate to severe liver problems

• you are taking fluoxetine or have taken it within the past 5 weeks

• you are taking selegiline or another MAOI (eg, phenelzine) or if you have taken any of these medicines within the past 14 days

• you are taking cyclobenzaprine, dextromethorphan, meperidine, methadone, propoxyphene, a selective serotonin reuptake inhibitor (SSRI) (eg, paroxetine), a serotonin-norepinephrine reuptake inhibitor (SNRI) (eg, venlafaxine, duloxetine), St. John's wort, a tetracyclic antidepressant (eg, mirtazapine), tramadol, trazodone, a tricyclic antidepressant (eg, amitriptyline), or vilazodone

Contact your doctor or health care provider right away if any of these apply to you.
 
How should this medicine be used?

 
General Dosing Recommendations

When AZILECT is prescribed as monotherapy or as adjunct therapy in patients not taking levodopa, patients may start AZILECT at the recommended dose of 1 mg administered orally once daily.
In patients taking levodopa, with or without other PD drugs (e.g., dopamineagonist, amantadine, anticholinergics), the recommended initial dose of AZILECT is 0.5 mg once daily. If the patient tolerates the daily 0.5 mg dose, but a sufficient clinical response is not achieved, the dose may be increased to 1 mg once daily. When AZILECT is used in combination with levodopa, a reduction of the levodopa dose may be considered, based upon individual response.
 
General information:

• If you have any questions about rasagiline, please talk with your doctor, pharmacist, or other health care provider.

• Rasagiline is to be used only by the patient for whom it is prescribed. Do not share it with other people.

• If your symptoms do not improve or if they become worse, check with your doctor.

• Check with your pharmacist about how to dispose of unused medicine.

This information should not be used to decide whether or not to take rasagiline or any other medicine.